| Dr Mark E Velarde, MD | |
|
6081 Hamilton Blvd Ste 101, Wescosville, PA 18106-9801 | |
| (610) 395-0600 | |
| (484) 403-4018 |
| Full Name | Dr Mark E Velarde |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 31 Years |
| Location | 6081 Hamilton Blvd Ste 101, Wescosville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578513560 | NPI | - | NPPES |
| P00221679 | Other | PA | PALMETTO GBA MEDICARE |
| 1521387 | Other | PA | GATEWAY HEALTH PLAN |
| 50046210 | Other | PA | CAPITAL BLUE CROSS |
| 682317 | Other | PA | HIGHMARK PA BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD063905L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Compassus - Allentown | Allentown, PA | Hospice |
| Lehigh Valley Hospice | Allentown, PA | Hospice |
| St Luke's Hospice | Bethlehem, PA | Hospice |
| Holisticare Hospice, Llc | Berwyn, PA | Hospice |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Cedarbrook Senior Care And Rehabilitation | Allentown, PA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
Native Hawaiians have higher rates of diabetes than other Asian-American/Pacific Islanders and are more likely to die at earlier ages from the disease and its complications than whites, the Honolulu Advertiser reports.
Paleo, high-protein, low-carb, gluten-free, vegetarian and vegan eating lifestyles have all exploded in popularity in the last few years. Whether people adopt these diets in order to lose weight or maintain overall wellness, consumers that follow them may be missing out on some essential nutrients. In the April issue of Food Technology Magazine, Linda Mila Ohr writes about the nutrient gaps in these various diets and how consumers can make sure they get the nutrients they need.
Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.
The addition of a GP clinic at hospitals should reduce waiting times in emergency departments, according to new research.
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
› Verified 4 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
Native Hawaiians have higher rates of diabetes than other Asian-American/Pacific Islanders and are more likely to die at earlier ages from the disease and its complications than whites, the Honolulu Advertiser reports.
Paleo, high-protein, low-carb, gluten-free, vegetarian and vegan eating lifestyles have all exploded in popularity in the last few years. Whether people adopt these diets in order to lose weight or maintain overall wellness, consumers that follow them may be missing out on some essential nutrients. In the April issue of Food Technology Magazine, Linda Mila Ohr writes about the nutrient gaps in these various diets and how consumers can make sure they get the nutrients they need.
Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.
The addition of a GP clinic at hospitals should reduce waiting times in emergency departments, according to new research.
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark E Velarde, MD 1605 N Cedar Crest Blvd, Suite 110b, Allentown, PA 18104-2351 Ph: (610) 973-1410 | Dr Mark E Velarde, MD 6081 Hamilton Blvd Ste 101, Wescosville, PA 18106-9801 Ph: (610) 395-0600 |
News Archive
Native Hawaiians have higher rates of diabetes than other Asian-American/Pacific Islanders and are more likely to die at earlier ages from the disease and its complications than whites, the Honolulu Advertiser reports.
Paleo, high-protein, low-carb, gluten-free, vegetarian and vegan eating lifestyles have all exploded in popularity in the last few years. Whether people adopt these diets in order to lose weight or maintain overall wellness, consumers that follow them may be missing out on some essential nutrients. In the April issue of Food Technology Magazine, Linda Mila Ohr writes about the nutrient gaps in these various diets and how consumers can make sure they get the nutrients they need.
Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.
The addition of a GP clinic at hospitals should reduce waiting times in emergency departments, according to new research.
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
› Verified 4 days ago